INVENTIVA (EPA:IVA) Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)
Transparency directive : regulatory news
06/07/2020 08:00